Atherosclerotic Cardiovascular Disease Clinical Trial
Official title:
Association Between Dietary Habits and Risk Factors for Atherosclerotic Cardiovascular Diseases in Assiut Governorate
Studying and investigating the association between dietary habits and risk factors for atherosclerotic cardiovascular diseases in Assiut governorate
Atherosclerotic cardiovascular diseases (ASCVD) has become the largest single cause of death
worldwide. It is responsible for an estimated 17 million deaths and led to 151 million
disability-adjusted life years (DALYs) lost (~30.0% of all deaths and 14.0% of all DALYs
lost).1 Further, by 2020, 32.0% of the world population deaths will be caused by ASCVD and by
2030; it's expected to be responsible for 33.0% of all deaths (24.2 million).2 Most of
atherosclerotic cardiovascular disease events nowadays are taking place in low- and
middle-income countries with 80% of the burden occurring in these countries.3
In Egypt, since 1990, ASCVD related mortality was increased over three folds; to be
responsible for over 40% of deaths compared with 12% reported two decades earlier.4 Egypt was
categorized as a "very-high-risk country for ASCVD" (according to 2016 ESC Guidelines on
cardiovascular disease prevention in clinical practice).5 According to (WHO 2014), ASCVD
related mortality in Egypt has been increased to account for 46% of total deaths.
Multiple risk factors are attributed to causing ASCVD. These risk factors fall into the
categories of either nonmodifiable or modifiable risk factors.6 Nonmodifiable risk factors
consist of those conditions that a person cannot alter, including age, heredity, ethnicity
and type 1 diabetes.
Whereas modifiable risk factors are conditions that can be altered by making certain
lifestyle changes.
In 2003, the Canadian Heart and Stroke Foundation identified nine major modifiable risk
factors for ASCVD, namely, tobacco smoking, alcohol abuse, physical inactivity, unhealthy
dietary habits, obesity, high BP, high concentrations of dietary fat and blood lipids, and
high blood glucose concentrations.7 Sudden stress, frequent migraine and the use of oral
contraceptives have also been identified as risk factors for the increased incidence of
coronary disease and stroke.8,9 The Egyptian National Hypertension Project (NHP)10,11 was
conducted between year 1991 and 1993 in six Egyptian governorates to define the prevalence of
ASCVD risk factors in adult Egyptians. The project documented an extremely high prevalence
and prominent clustering of ASCVD risk factors in adult men and women particularly obesity.
Since that time, and despite the increasing ASCVD related morbidity and mortality in our
Egyptian society, as mentioned before, there's no recent studies (up to our knowledge) was
conducted to determine the risk factors associated to ASCVD.
This study overall aim is to systematically explore and investigate the association between
dietary habits and risk factors for atherosclerotic cardiovascular diseases in Assiut
governorate.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01572259 -
Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism
|
Phase 3 | |
Completed |
NCT05792787 -
Association Between Apical Periodontitis and Atherosclerotic Cardiovascular Diseases
|
||
Completed |
NCT03911284 -
The Learning Registry
|
||
Recruiting |
NCT06048588 -
YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03705234 -
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
|
Phase 3 | |
Completed |
NCT03096288 -
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
|
Phase 4 | |
Enrolling by invitation |
NCT05485961 -
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
|
Phase 2/Phase 3 | |
Completed |
NCT01663402 -
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
|
Phase 3 | |
Completed |
NCT03597412 -
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
|
Phase 4 | |
Completed |
NCT05974345 -
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
|
||
Active, not recruiting |
NCT05030428 -
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
|
Phase 3 | |
Completed |
NCT00185185 -
Olmesartan Medoxomil in Atherosclerosis
|
Phase 3 | |
Completed |
NCT05129241 -
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
|
||
Completed |
NCT02991118 -
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
|
Phase 3 | |
Completed |
NCT05639244 -
Time Restricted Eating and Innate Immunity
|
N/A | |
Completed |
NCT02988115 -
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
|
Phase 3 | |
Recruiting |
NCT04215237 -
How Atorvastatin Affects the Gut Flora and Metabolomics?
|
N/A | |
Completed |
NCT05355402 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
|
Phase 2 | |
Recruiting |
NCT05726838 -
The Belgian REAL (BE.REAL) Registry
|
||
Active, not recruiting |
NCT04462159 -
The Young Heart Study
|
N/A |